देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
ROSUVASTATIN (ROSUVASTATIN CALCIUM)
TEVA CANADA LIMITED
C10AA07
ROSUVASTATIN
10MG
TABLET
ROSUVASTATIN (ROSUVASTATIN CALCIUM) 10MG
ORAL
30/100/500
Prescription
HMG-COA REDUCTASE INHIBITORS
Active ingredient group (AIG) number: 0148963001; AHFS:
APPROVED
2012-03-15
TEVA-ROSUVASTATIN (Rosuvastatin Calcium Tablets) Page 1 of 59 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR TEVA-ROSUVASTATIN Rosuvastatin Calcium Tablets Tablets, 5 mg, 10 mg, 20 mg and 40 mg rosuvastatin (rosuvastatin calcium), Oral Teva Standard Lipid Metabolism Regulator Teva Canada Limited 30 Novopharm Court Toronto, ON M1B 2K9 Canada www.tevacanada.com Date of Initial Authorization: March 15, 2012 Date of Revision: January 23, 2023 Submission Control Number: 268778 TEVA-ROSUVASTATIN (Rosuvastatin Calcium Tablets) Page 2 of 59 RECENT MAJOR LABEL CHANGES Not applicable TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES .............................................................................................. 2 TABLE OF CONTENTS ................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ..................................................................................................................... 4 1.1 Pediatrics ..................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS ........................................................................................................ 5 4 DOSAGE AND ADMINISTRATION ........................................................................................ 5 4.1 Dosing Considerations .................................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ............................................................... 5 4.4 Administration .................................................................... पूरा दस्तावेज़ पढ़ें